Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHiscox Regulatory News (HSX)

Share Price Information for Hiscox (HSX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,112.00
Bid: 1,111.00
Ask: 1,113.00
Change: -2.00 (-0.18%)
Spread: 2.00 (0.18%)
Open: 1,109.00
High: 1,121.00
Low: 1,108.00
Prev. Close: 1,114.00
HSX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Extraordinary General Meeting

18 Mar 2014 15:30

RNS Number : 6048C
Hiscox Ltd
18 March 2014
 



 

Proposed Return of Capital to Shareholders

 

Hamilton, Bermuda (18 March 2014) - Further to the announcements on 24 and 25 February 2014 Hiscox Ltd ("Hiscox" or the "Company") is pleased to announce the results of the Extraordinary General Meeting ("EGM") held earlier today and the consequential approval of the Return of Capital to Shareholders.

 

Result of Extraordinary General Meeting

 

All of the resolutions set out in the Notice of EGM set out in the Circular to Shareholders dated 25 February 2014 (the "Circular") were duly passed on a show of hands at the meeting held at 2.00 p.m. (Guernsey time) earlier today. Shareholders have accordingly approved the proposed Return of Capital by way of a special distribution to Shareholders of 36 pence per ordinary share and a further amount of 14 pence per ordinary share, instead of the payment of a final dividend for the financial year ended 31 December 2013.

 

As a result of the passing of the resolutions at the EGM the Company will issue to Shareholders on the register at 4.30 p.m. on 18 March 2014 either one C share of par value 0.01 pence in the capital of the Company ("C Share") or one D share of par value 0.01 in the capital of the Company ("D Share") per Existing Ordinary Share and the 89 for 100 Share Capital Consolidation will be implemented with respect to Shareholders. Further details of the resolutions are set out in the Circular.

 

In accordance with Listing Rule 9.6.2R copies of all resolutions passed at the EGM have been submitted to the National Storage Mechanism and will shortly be available to view at www.hemscott.com/nsm.do.

 

Details of the proxy votes lodged in favour of the Chairman are set out below:

 

Resolution

For

%

Against

%

Withheld

 

 

 

 

 

 

1. To approve the Return of Capital as described in the Circular including the approval of the Option Agreement

261,161,880

99.99

1,184

0.01

1,656,933

2. To authorise the Directors to allot Ordinary Shares

253,804,017

96.77

8,468,450

3.23

549,530

3. To disapply pre-emption rights

 

262,271,432

99.99

412

0.01

550,153

4. To authorise the Company to make market purchases of Ordinary Shares

262,271,626

99.99

218

0.01

550,153

 

Results of Return of Capital

 

Further details as to the results of the Return of Capital including the number of C Shares and D Shares issued to Shareholders as a result of the passing of the resolutions at the EGM and the elections from Shareholders received by the Election Deadline of 1.00 p.m. on 18 March 2014 will be announced by the Company as soon as possible.

 

Further details of the Return of Capital are contained in the Circular. Terms used in this announcement have the same meaning as set out in the Circular.

 

 

 

For further information:

Hiscox Ltd

Jeremy Pinchin, Group Company Secretary +1 441 278 8300

Kylie O'Connor, Head of Group Communications, London +44 (0)20 7448 6656

 

This announcement does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

 

The release, publication or distribution of this announcement in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this announcement is released, published or distributed should inform themselves about and observe such restrictions.

 

No application will be made to the UK Listing Authority or to the London Stock Exchange for any of the C Shares, D Shares, C Deferred Shares or Deferred Shares to be admitted to the Official List or to trading on the London Stock Exchange's main market for listed securities, nor will the C Shares, D Shares, C Deferred Shares or Deferred Shares be admitted to trading on any other recognised investment exchange.

 

None of the C Shares, D Shares, C Deferred Shares, Deferred Shares or New Ordinary Shares have been or will be registered under the United States Securities Act of 1933 as amended (the "US Securities Act") or the state securities laws of the United States and none of them may be offered or sold in the United States unless pursuant to a transaction that has been registered under the US Securities Act and the relevant state securities laws or that is not subject to the registration requirements of the US Securities Act or such laws, either due to an exemption therefrom or otherwise.

 

None of the C Shares, D Shares, C Deferred Shares, Deferred Shares, New Ordinary Shares or this announcement or the Circular has been approved, disapproved or otherwise recommended by any US federal or state securities commission, including the U.S. Securities and Exchange Commission, or other regulatory authority or any non-US securities commission or regulatory authority, nor have such authorities confirmed the accuracy or determined the adequacy of this announcement or the Circular. Any representation to the contrary is a criminal offence in the United States.

 

UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority in the United Kingdom and acting as financial adviser and corporate broker exclusively for the Company and for no one else in connection with the matters referred to in this announcement or the Circular and will not be responsible to anyone other than the Company (whether or not a recipient of this announcement or the Circular) for providing the protections afforded to clients of UBS Limited nor for providing advice in relation to the matters referred to in this announcement or the Circular or any other matter referred to in this announcement or the Circular. Persons other than the Company are recommended to seek their own financial and professional advice.

 

Apart from the responsibilities and liabilities, if any, which may be imposed on UBS Limited by the Financial Services and Markets Act 2000 (as amended) or the regulatory regime established thereunder, UBS Limited accepts no responsibility or liability, whether arising in tort, contract or otherwise, to Shareholders for the contents of this announcement or the Circular or for any other statement made in connection with the Company, the proposed Return of Capital or the Resolutions. 

 

This announcement has been issued by, and is the sole responsibility of, the Company.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
REGJPMATMBBBBLI
Date   Source Headline
22nd Jul 20217:00 amRNSAki Hussain to succeed Bronek Masojada as CEO
1st Jul 202112:36 pmRNSTotal Voting Rights
30th Jun 202112:44 pmRNSTR-1 Standard form-notification major shareholding
28th Jun 20215:17 pmRNSResult of Meeting
14th Jun 20211:18 pmRNSDirector/PDMR Shareholding
7th Jun 20211:41 pmRNSTR-1:Standard form notification major shareholding
4th Jun 20212:27 pmRNSDirector/PDMR Shareholding
3rd Jun 20211:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202110:30 amRNSNotice of Meeting
3rd Jun 202110:30 amRNSConsent Solicitation
3rd Jun 20217:00 amRNSLegacy Reinsurance Deal
1st Jun 202111:46 amRNSTotal Voting Rights
14th May 20217:00 amRNSAGM Results
13th May 202112:33 pmRNSSyndicates 33 and 6104 – results and estimates
5th May 20217:00 amRNSTrading Statement
20th Apr 202111:51 amRNSDirector/PDMR Shareholding
16th Apr 202112:47 pmRNSDirector/PDMR Shareholding
13th Apr 202111:41 amRNSNotice of 2021 Annual General Meeting
12th Apr 20212:57 pmRNSDirector/PDMR Shareholding
1st Apr 20213:55 pmRNSTotal Voting Rights
24th Mar 20217:00 amRNSDirector/PDMR Shareholding
22nd Mar 202112:49 pmRNSDirector/PDMR Shareholding
17th Mar 20217:00 amRNS2020 Annual Report
15th Mar 20216:28 pmRNSDirector/PDMR Shareholding
15th Mar 20216:13 pmRNSDirector/PDMR Shareholding
11th Mar 20217:00 amRNSTR-1:Standard form-notification major shareholding
3rd Mar 20217:01 amRNSFull Year Results
3rd Mar 20217:00 amRNSSyndicates 33 and 6104 – results and estimates
27th Jan 202111:21 amRNSTR-1:Standard form-notification major shareholding
15th Jan 202110:40 amRNSHiscox Ltd response to Supreme Court Judgment
11th Jan 20211:01 pmRNSDirector/PDMR Shareholding
4th Jan 202112:36 pmRNSTotal Voting Rights
1st Dec 202011:56 amRNSTotal Voting Rights
26th Nov 202011:40 amRNSDirector/PDMR Shareholding
6th Nov 20207:00 amRNSSyndicates 33 and 6104 – results and estimates
2nd Nov 20207:00 amRNSHiscox Ltd trading statement
12th Oct 202011:22 amRNSTR-1: Standard form-notification of major holdings
1st Oct 202011:48 amRNSTotal Voting Rights
1st Oct 202011:40 amRNSDirector/PDMR Shareholding
29th Sep 20207:13 amRNSUpdate on UK Insurance Industry Test Case
16th Sep 202011:54 amRNSNotification of transactions by PDMR
15th Sep 202011:25 amRNSResponse to Insurance Industry Test Case Judgment
14th Sep 20204:35 pmRNS2021 Syndicate Business Forecast
7th Aug 20207:00 amRNSCorrection: Syndicate results and estimates
3rd Aug 20207:01 amRNSHiscox Ltd interim results
3rd Aug 20207:00 amRNSSyndicates 33 and 6104 – results and estimates
22nd Jun 20205:27 pmRNSTR-1: Standard form-notification of major holdings
19th Jun 202012:19 pmRNSRights Attaching to Equity Shares
9th Jun 20204:27 pmRNSTR-1: Standard form-notification of major holdings
3rd Jun 202012:03 pmRNSTR-1: Standard form-notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.